Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific
NCT02442349
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
171
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG:
AZD9291
Sponsor
AstraZeneca